Skip to main content

Summary

for people ages 1–18 (full criteria)
at San Francisco, California and other locations
study started
estimated completion:

Description

Summary

This is a multicentre, extension study of LUM001 in children diagnosed with Alagille Syndrome who have completed participation in a core LUM001 treatment protocol. The primary objective is to evaluate long-term safety and tolerability of LUM001. Efficacy will be assessed by evaluating the effect of LUM001 on the biochemical markers and pruritus associated with Alagille Syndrome.

Official Title

A Multicenter Extension Study to Evaluate the Long-Term Safety and Durability of the Therapeutic Effect of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome

Keywords

Alagille Syndrome

Eligibility

You can join if…

Open to people ages 1–18

  1. Male or female, 12 months to 18 years of age.
  2. Completed participation in the LUM001-301 protocol.
  3. Females of childbearing potential must have a negative urine pregnancy test at the Baseline Visit.
  4. Sexually active females must be prepared to use an effective method of contraception during the trial.
  5. Caregivers (and age appropriate subjects) must have access to phone for scheduled calls from study site.
  6. Caregivers (and age appropriate subjects) must be willing and able to complete a daily electronic diary.

You CAN'T join if...

  1. Experienced an adverse event or serious adverse event (SAE) related to the study drug during the LUM001-301 protocol that led to the discontinuation of the subject from the core study.
  2. Any conditions or abnormalities which may compromise the safety of the subject, or interfere with the subject participating in or completing the study.
  3. History or presence of gallstones or kidney stones.
  4. History of non-adherence during the subject's participation in the LUM001-301 protocol. Non-adherence is defined by dosing compliance1 of less than 80% in the LUM001-301 protocol.

Locations

  • Children's Hospital Los Angeles
    Los Angeles, California, 90027, United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Shire
ID
NCT02117713
Phase
Phase 2
Lead Scientist
Philip Rosenthal
Study Type
Interventional
Last Updated
April 1, 2017